Maze Therapeutics (NASDAQ:MAZE) Shares Up 4.5% – Still a Buy?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) rose 4.5% on Monday. The company traded as high as $26.91 and last traded at $27.2110. Approximately 354,721 shares traded hands during trading, a decline of 46% from the average session volume of 662,192 shares. The stock had previously closed at $26.05.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MAZE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Wedbush reaffirmed an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Citigroup initiated coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday. Finally, Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Trading Up 3.5%

The firm has a market capitalization of $1.50 billion, a PE ratio of -10.68 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The company has a fifty day moving average of $27.12 and a 200-day moving average of $28.91.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 11,411 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $296,800.11. Following the transaction, the chief executive officer owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. This trade represents a 29.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Courtney Phillips sold 2,012 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the sale, the insider owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 183,959 shares of company stock valued at $5,053,389 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. lifted its stake in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the last quarter. TRV GP IV LLC bought a new stake in Maze Therapeutics in the second quarter worth $133,502,907. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the second quarter worth $122,983,582. BlackRock Inc. acquired a new position in Maze Therapeutics during the second quarter worth $104,525,000. Finally, Jupiter Topco LLC bought a new position in Maze Therapeutics during the second quarter valued at about $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.